Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Johnson and Johnson
Federal Trade Commission
US Department of Justice
AstraZeneca
Queensland Health
Cerilliant
UBS
Fuji

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,028,071

« Back to Dashboard

Which drugs does patent 6,028,071 protect, and when does it expire?

Patent 6,028,071 protects FOLOTYN and is included in one NDA.

This patent has twelve patent family members in nine countries.
Summary for Patent: 6,028,071
Title: Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
Abstract:Highly purified 10-propargyl-10-deazaaminopterin (10-propargyl-10dAM) compositions tested in xenograft models for their efficacy against human tumors are shown to be far superior to methotrexate ("MTX") and are even superior to the newer clinical candidate edatrexate ("EDX"). Moreover, 10-propragyl-10dAM showed a surprising ability to cure tumors such that there was no evidence of tumor growth several weeks after the cessation of therapy. Thus, highly purified compositions containing 10-propargyl-10dAM can be used to treat human tumors, particularly human mammary tumors and human lung cancer.
Inventor(s): Sirotnak; Francis M. (New York, NY), Piper; James R. (Birmingham, AL), DeGraw; Joseph I. (Missoula, MT), Colwell; William T. (Menlo Park, CA)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY) SRI International (Menlo Park, CA) Southern Research Institute (Birmingham, AL)
Application Number:09/214,984
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,028,071
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,028,071

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allos FOLOTYN pralatrexate SOLUTION;INTRAVENOUS 022468-001 Sep 24, 2009 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA ➤ Sign Up
Allos FOLOTYN pralatrexate SOLUTION;INTRAVENOUS 022468-002 Sep 24, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,028,071

PCT Information
PCT FiledJuly 16, 1997PCT Application Number:PCT/US97/11982
PCT Publication Date:January 22, 1998PCT Publication Number: WO98/02163

Non-Orange Book US Patents Family Members for Patent 6,028,071

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,323,205 Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Teva
Mallinckrodt
McKinsey
McKesson
Moodys
Healthtrust
Cerilliant
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.